| 1.18 0.01 (0.85%) | 05-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.71 | 1-year : | 2 |
| Resists | First : | 1.47 | Second : | 1.71 |
| Pivot price | 1.09  |
|||
| Supports | First : | 1 |
Second : | 0.72 |
| MAs | MA(5) : | 1.14 |
MA(20) : | 1.03 |
| MA(100) : | 1.26 |
MA(250) : | 1.8 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 50.7 |
D(3) : | 48.5 |
| RSI | RSI(14): 59 |
|||
| 52-week | High : | 17.75 | Low : | 0.65 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ATNF ] has closed below upper band by 32.2%. Bollinger Bands are 7.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.27 - 1.27 | 1.27 - 1.28 |
| Low: | 1.09 - 1.09 | 1.09 - 1.1 |
| Close: | 1.17 - 1.18 | 1.18 - 1.19 |
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Thu, 01 May 2025
180 Life Sciences nears patent for post-surgery cognitive aid - Investing.com
Thu, 01 May 2025
Patent Breakthrough: 180 Life Sciences Develops First Treatment to Prevent Post-Surgery Cognitive Decline in Elderly - Stock Titan
Wed, 30 Apr 2025
180 Life Sciences Corp. Announces Share Repurchase - ACCESS Newswire
Wed, 30 Apr 2025
180 Life Sciences Corp. Announces Share Repurchase | ATNF Stock News - GuruFocus
Wed, 30 Apr 2025
180 Life Sciences Launches Massive 23% Share Reduction Plan: Key Details of $1M Strategic Buyback - Stock Titan
Sun, 27 Apr 2025
Press Release Distribution & PR Platform - ACCESS Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 48.9 (%) |
| Held by Institutions | 31 (%) |
| Shares Short | 89 (K) |
| Shares Short P.Month | 57 (K) |
| EPS | -15.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.91 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -43.9 % |
| Return on Equity (ttm) | -135.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.08 |
| PEG Ratio | 0 |
| Price to Book value | 0.4 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.55 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|